Table 3.
The Mean Discriminations of Diverse Models After 5-Fold Cross-Validation for Identifying 2-Year Recrudescence
| Model | Training Cohort (n = 258) | Validation Cohort (n = 65) | ||||
|---|---|---|---|---|---|---|
| AUC (95% CI) | NRI | P (NRI) | AUC (95% CI) | NRI | P (NRI) | |
| Radiomics | 0.939(0.908–0.973) | 61.8% | <0.001 | 0.842(0.736–0.951) | 51.3% | <0.001 |
| Clinicoradiogic | 0.694(0.660–0.726) | 7.3% | 0.004 | 0.707(0.627–0.759) | 15.5% | 0.002 |
| TNM stage | 0.624(0.590–0.659) | 9.4% | 0.007 | 0.626(0.555–0.694) | 13.7% | 0.041 |
| BCLC stage | 0.586(0.551–0.620) | 1.9% | 0.347 | 0.587(0.517–0.654) | 8.2% | 0.209 |
| ERASL-pre risk | 0.538(0.503–0.574) | −4.3% | 0.990 | 0.538(0.467–0.610) | 1.9% | 0.268 |
| ERASL-post risk | 0.560(0.531–0.604) | Ref | Ref | 0.529(0.495–0.640) | Ref | Ref |
| Radiomics vs Clinicoradiologic | / | 54.5% | <0.001 | / | 35.9% | <0.001 |
| Radiomics vs TNM stage | / | 52.4% | <0.001 | / | 37.7% | <0.001 |
| Radiomics vs BCLC stage | / | 59.8% | <0.001 | / | 43.2% | <0.001 |
| Radiomics vs ERASL-pre risk | / | 66.1% | <0.001 | / | 49.4% | <0.001 |
Abbreviations: AUC, area under receiver operating characteristic curve; CI, confidence interval; NRI, net reclassification improvement; Ref, reference; BCLC, the Barcelona Clinic Liver Cancer staging system; TNM, the tumor-node-metastasis system; ERASL-pre and ERASL-post risk, the preoperative and postoperative risks of Early Recurrence After Surgery for Liver tumor.